KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Debt to Equity (2016 - 2025)

Historic Debt to Equity for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $0.07.

  • West Pharmaceutical Services' Debt to Equity fell 976.71% to $0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.07, marking a year-over-year decrease of 976.71%. This contributed to the annual value of $0.08 for FY2024, which is 19891.24% up from last year.
  • Latest data reveals that West Pharmaceutical Services reported Debt to Equity of $0.07 as of Q3 2025, which was down 976.71% from $0.07 recorded in Q2 2025.
  • West Pharmaceutical Services' Debt to Equity's 5-year high stood at $0.14 during Q1 2021, with a 5-year trough of $0.03 in Q4 2023.
  • For the 5-year period, West Pharmaceutical Services' Debt to Equity averaged around $0.08, with its median value being $0.08 (2024).
  • As far as peak fluctuations go, West Pharmaceutical Services' Debt to Equity crashed by 6717.72% in 2023, and later skyrocketed by 19891.24% in 2024.
  • West Pharmaceutical Services' Debt to Equity (Quarter) stood at $0.11 in 2021, then fell by 28.94% to $0.08 in 2022, then crashed by 67.18% to $0.03 in 2023, then skyrocketed by 198.91% to $0.08 in 2024, then dropped by 12.06% to $0.07 in 2025.
  • Its last three reported values are $0.07 in Q3 2025, $0.07 for Q2 2025, and $0.08 during Q1 2025.